Medivir
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
| Company type | Public limited company |
|---|---|
| Nasdaq Stockholm: MVIR B | |
| Industry | Biotechnology |
| Founded | 1988 |
| Headquarters | Huddinge, Sweden |
Area served | Global |
Key people | Uli Hacksell (CEO) |
| Products | Oncological R&D |
| Revenue | 658 MM SEK (2015) |
Number of employees | 15 |
| Website | www.medivir.com |
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.